| Active Not Recruiting | A Study to Evaluate AI-09 In Participants With Glabellar Lines NCT07321834 | Eirion Therapeutics Inc. | Phase 2 |
| Completed | Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure NCT07398755 | Yuvell | — |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines NCT07013279 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Completed | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult NCT06834789 | AbbVie | Phase 1 |
| Completed | Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines NCT06246552 | Jetema USA Inc. | Phase 2 |
| Recruiting | To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) NCT06205797 | Huons Biopharma | Phase 3 |
| Completed | A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus NCT06946160 | Espad Pharmed | Phase 3 |
| Completed | A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines NCT06308198 | AbbVie | Phase 3 |
| Completed | A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatme NCT07374965 | Yuvell | — |
| Unknown | Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar L NCT05801146 | Hugel | Phase 3 |
| Completed | Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines NCT06212960 | Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Completed | Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial NCT05804656 | CKD Bio Corporation | Phase 3 |
| Completed | A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult NCT05496335 | AbbVie | Phase 1 |
| Completed | Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines NCT05428930 | CKD Bio Corporation | Phase 1 |
| Completed | Phase 2 of HU-045 in Glabellar Lines NCT05298449 | Huons Co., Ltd. | Phase 2 |
| Completed | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult NCT05248867 | AbbVie | Phase 3 |
| Completed | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin NCT05248880 | AbbVie | Phase 3 |
| Completed | A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Li NCT05248893 | AbbVie | Phase 3 |
| Completed | Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines NCT05292638 | CKD Bio Corporation | Phase 1 |
| Completed | Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin NCT05089357 | Galderma R&D | — |
| Completed | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Pa NCT05100199 | Allergan | Phase 2 |
| Completed | A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines NCT05013424 | Allergan | Phase 2 |
| Completed | To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar NCT04944953 | Hugel | Phase 1 |
| Completed | Treatment of Moderate to Severe Glabellar Lines (BMI2006) NCT05531968 | BMI Korea | Phase 3 |
| Completed | Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines NCT04225260 | Galderma R&D | Phase 3 |
| Completed | MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) NCT04157686 | Medy-Tox | Phase 3 |
| Completed | AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines NCT04096326 | Allergan | Phase 2 |
| Completed | MT10109L in the Treatment of Glabellar Lines NCT03795922 | Medy-Tox | Phase 3 |
| Completed | MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines NCT03732833 | Medy-Tox | Phase 3 |
| Completed | MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Line NCT03721016 | Medy-Tox | Phase 3 |
| Unknown | Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension NCT03184363 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Completed | Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. NCT05380154 | Hugel | Phase 3 |
| Completed | The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines NCT02961673 | Huons Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Li NCT02718118 | Galderma R&D | Phase 4 |
| Completed | Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lin NCT03216408 | Medy-Tox | Phase 3 |
| Completed | Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabell NCT02493946 | Ipsen | Phase 3 |
| Completed | Dysport in the Treatment of Glabellar Lines in Chinese Subjects NCT02450526 | Ipsen | Phase 3 |
| Completed | Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® NCT02353897 | Ipsen | — |
| Completed | Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY NCT02176356 | Allergan | Phase 4 |
| Completed | BOTOX® in the Treatment of Upper Facial Lines in Japan NCT01797094 | Allergan | Phase 3 |
| Completed | Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX® NCT01608672 | Allergan | — |
| Completed | Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines NCT01224015 | Allergan | Phase 3 |
| Completed | Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines NCT01189760 | Allergan | Phase 3 |
| Completed | Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines NCT01271452 | Allergan | Phase 4 |
| Completed | Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea NCT02043145 | Allergan | — |
| Completed | Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines NCT00512135 | Merz Pharmaceuticals GmbH | Phase 3 |
| Completed | A Study Of BOTOX For The Treatment Of Glabellar Lines NCT00408785 | GlaxoSmithKline | Phase 3 |